2025年中国—新西兰生物医药领域双边研讨会会议纪要
Minutes of the Bilateral Seminar on Biopharmaceuticals between China and New Zealand in 2025
会议时间：2025 年 6 月 27 日 13:30-16:30
Meeting Time: June 27, 2025, 1:30-4:30 PM
会议地点：广州汇华希尔顿逸林酒店一楼上海厅
Meeting Venue: Shanghai Hall, First Floor, Huihua Hilton Garden Hotel, Guangzhou
主办单位：中国科学院、新西兰商业、创新和就业部
Organizing Units: Chinese Academy of Sciences, New Zealand Ministry of Business, Innovation and Employment
参会人员：中国科学院广州生物医药与健康研究院、中国科学院国际合作局、新西兰商业、创新就业部、奥克兰大学、奥塔哥大学、惠灵顿维多利亚大学、林肯大学、马拉格汉医学研究所、梅西大学、坎特伯雷大学代表。
Attendees: Representatives from the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH), the International Cooperation Bureau of the Chinese Academy of Sciences, the Ministry of Business, Innovation and Employment of New Zealand, the University of Auckland, the University of Otago, Victoria University of Wellington, Lincoln University, Malaghan Institute of Medical Research, Massey University, and the University of Canterbury.
会议记录：Georgia Carson、吴绮婷
Recorders: Georgia Carson, Wu Qiting
2025年6月27日下午，中国科学院广州生物医药（GIBH）与健康研究院和新西兰莫里斯·威尔金斯中心（MWC）共同承办召开了2025年中国—新西兰生物医药领域双边研讨会。2025年度双边研讨会聚焦生物医药领域，诚邀中新双方科研工作者进行学术交流与深入探讨，旨在进一步深化双方在该领域的合作。会议相关事项具体纪要如下：
On the afternoon of June 27, 2025, the 2025 China-New Zealand Bilateral Symposium in the Biomedical Field was jointly hosted by the Guangzhou Institute of Biomedicine and Health (GIBH) and the Maurice Wilkins Centre (MWC). The symposium focused on the biomedical field and invited researchers from both China and New Zealand to engage in academic exchanges and in-depth discussions, aiming to further deepen cooperation in this field. The following are the specific records of the meeting:
开幕致辞
Opening Remarks
王振宇（中国科学院国际合作局副局长）通过视频代表中科院国际合作局对与会者的参与和付出表示欢迎与感谢，并强调本次研讨会是基于2019年签署、2023年续签的《新西兰商业、创新和就业部和中国科学院关于科学和研究的安排备忘录》的关键活动。他指出，两国在基础研究、先进技术及临床试验等领域具有互补优势，并已取得显著成果，希望未来继续携手合作，互惠互利，共同进步。最后预祝本次研讨会取得圆满成功。
Wang Zhenyu (Deputy Director of the International Cooperation Bureau of the Chinese Academy of Sciences) expressed his welcome and gratitude to the participants via video on behalf of the International Cooperation Bureau of the Chinese Academy of Sciences. He emphasized that this seminar is a key activity based on the Memorandum of Understanding on Science and Research between the Ministry of Business, Innovation and Employment of New Zealand and the Chinese Academy of Sciences, which was signed in 2019 and renewed in 2023. He pointed out that both countries have complementary advantages in basic research, advanced technologies, and clinical trials, and have achieved significant results. He hopes that both sides will continue to cooperate in the future, benefiting each other, and make joint progress. Finally, he wished the seminar a great success.
Hugo Bussell（新西兰商业、创新就业部国际科学合作经理）通过视频回顾了中新两国在植物、食品、海洋研究及生物医学领域的长期合作历史，并表达了对未来健康领域合作的期待。他特别感谢莫里斯·威尔金斯中心及中方合作伙伴的努力，并希望本次研讨会能促成更多优秀合作项目。
Hugo Bussell (International Science Cooperation Manager of the Ministry of Business, Innovation and Employment of New Zealand) reviewed the long-term cooperation between China and New Zealand in plant, food, marine research, and biomedicine via video, and expressed expectations for future cooperation in the health sector. He particularly thanked the Maurice Wilkins Centre and Chinese partners for their efforts and hoped that the seminar would lead to more excellent collaborative projects.
孙飞（广州健康院副院长）回顾了广州健康院与新西兰研究机构的合作历程，包括2021年成立的中国-新西兰生物医药与健康“一带一路”联合实验室，该实验室聚焦干细胞与再生医学研究、肿瘤生物治疗、代谢疾病治疗、药物研发以及传染病防治五大领域。他提到了双方获得的研究成果，包括：中国研发的靶向CD19的第三代CAR-T细胞治疗淋巴瘤已在新西兰完成一期临床试验并进入二期；同时赖良学教授的异种器官移植研究成果——奥克兰猪模型，促成了中国-新西兰-德国三方合作。此外，孙飞还宣布今年优化了联合实验室管理结构，优先纳入年轻研究人员，组建了由20名PI组成的中方固定研究团队，并成立由丁克、刘澎涛、Dave Grattan等知名专家组成的学术委员会，帮助联合实验室开展学术活动以及为联合研究制定计划。再次感谢新方2024年皇后镇学术研讨会的邀请并预祝本次研讨会的成功。
Sun Fei (Vice Director of the Guangzhou Institute of Health) reviewed the cooperation history between the Guangzhou Institute of Health and New Zealand research institutions, including the China-New Zealand Biomedical and Health "Belt and Road" Joint Laboratory established in 2021, which focuses on stem cell and regenerative medicine research, tumor biologic therapy, metabolic disease treatment, drug development, and infectious disease prevention and control. He mentioned the research outcomes achieved by both sides, including: the third-generation CAR-T cell therapy targeting CD19 developed by China has completed Phase I clinical trials in New Zealand and entered Phase II; and the xenograft organ transplantation research results of Professor Li Liangxue, the Auckland pig model, facilitated a tripartite cooperation between China, New Zealand, and Germany. Additionally, Sun Fei announced that the joint laboratory management structure was optimized this year, prioritizing the inclusion of young researchers, forming a fixed research team of 20 PIs from China, and establishing an academic committee composed of renowned experts such as Ding Ke, Liu Pengtao, and Dave Grattan to help the joint laboratory conduct academic activities and plan joint research. He once again thanked the New Zealand delegation's invitation to the Queenstown academic seminar in 2024 and wished the seminar a great success.
Emily Parker（新方高校和科研机构代表）表示，这是新西兰派往中国的最大规模代表团，涵盖资深科学家和青年学者。她强调，本次研讨会是根据中新安排备忘录举办的规模最大一次活动，旨在规划未来的合作方向，并希望通过此次活动促进双方科学家之间的深入交流。
Emily Parker (representative of New Zealand's universities and research institutions) stated that this is the largest delegation sent by New Zealand to China, including senior scientists and young scholars. She emphasized that this seminar is the largest activity held according to the Memorandum of Understanding between China and New Zealand, aimed at planning future cooperation directions, and hopes to promote in-depth exchanges among scientists from both sides through this event.
代表性学术报告
Representative academic reports
李鹏作了以《Developing new CAR-T cell therapies for cancer
Li Peng presented on "Developing New CAR-T Cell Therapies for Cancer"
Treatment》为题的报告，详细介绍了其团队在CAR-T细胞疗法上的进展，包括与新西兰伙伴合作开发的WTL-002 CAR-T项目。他提到，自2015年起，双方通过多次互访建立了深厚的合作关系，并成功获得新西兰政府资助，在新西兰启动了一期临床试验。目前，二期临床试验正在新西兰多点进行，已有超过十人接受治疗。针对实体瘤治疗面临的抗原异质性和肿瘤微环境问题，李鹏提出利用iTNK策略，通过基因编辑或化学抑制剂将T细胞重编程为具有自然杀伤细胞特征的iTNK细胞，增强CAR-T细胞在肿瘤微环境中的浸润和存活能力，从而提高疗效。他表示未来将继续与孔祥谦合作开发新型抑制剂，并希望能与Jeff Smaill和Emily Parker合作。
The report, titled "Progress in CAR-T Cell Therapy," detailed the advancements made by his team in CAR-T cell therapy, including the WTL-002 CAR-T project developed in collaboration with New Zealand partners. He mentioned that since 2015, the 双方通过多次互访建立了深厚的合作关系，并成功获得新西兰政府资助，在新西兰启动了一期临床试验. currently, phase II clinical trials are being conducted at multiple sites in New Zealand, with over ten patients having received treatment. Addressing the challenges of antigen heterogeneity and the tumor microenvironment in treating solid tumors, Li Peng proposed using the iTNK strategy, which involves reprogramming T cells into iTNK cells with natural killer cell characteristics through gene editing or chemical inhibitors. This approach aims to enhance the infiltration and survival of CAR-T cells in the tumor microenvironment, thereby improving therapeutic efficacy. He stated that he plans to continue collaborating with Kang Xiangqian to develop new inhibitors and expressed a desire to work with Jeff Smaill and Emily Parker.
彭广敦作了以《Spatial mapping of cancer heterogeneity》为题的报告，探讨了癌症异质性空间图谱的研究方法，介绍了其团队的创新成果。彭广敦及其团队发明的 Geo-seq、Share-seq 和 MISAR-seq 等空间绘图技术，实现在同一组织上进行空间多组学分析，广泛应用于癌症生物学、发育免疫学等领域。在肿瘤微环境研究中，该方法助力理解肿瘤异质性和空间相互作用，对多种肿瘤进行分析，并通过空间绘制组蛋白修饰测试药物反应。此外，他表示，团队还开发了用于绘制单细胞表达/染色质特征、肿瘤浸润性淋巴细胞（TIL）生态位和细胞间相互作用图谱的算法，并与GIBH的空间生物学平台合作。
Peng Guangdun gave a presentation titled "Spatial Mapping of Cancer Heterogeneity," discussing the research methods for studying spatial maps of cancer heterogeneity and introducing the innovative achievements of his team. Peng Guangdun and his team have invented spatial mapping technologies such as Geo-seq, Share-seq, and MISAR-seq, which enable spatial multi-omics analysis on the same tissue. These technologies are widely applied in fields such as cancer biology and developmental immunology. In tumor microenvironment research, this method helps to understand tumor heterogeneity and spatial interactions, allowing for the analysis of multiple types of tumors and testing drug responses through spatial mapping of histone modifications. Additionally, he mentioned that the team has developed algorithms for mapping single-cell expression/染色质特征, tumor-infiltrating lymphocyte (TIL) niches, and cell-cell interactions, and has collaborated with GIBH's spatial biology platform.
圆桌会议
Roundtable Discussion
在圆桌会议期间，来自新方的10名研究人员和来自中方的6名研究人员分别发表了主题演讲，内容涉及传染病防控、疫苗开发、代谢疾病与表型调控、肿瘤精准诊疗、神经退行性疾病、药物研发技术、生殖发育等多个前沿领域。他们均表达了在这些研究方向上开展合作的意愿。圆桌会议后，中新双方展开了热烈的讨论。孙飞院长建议Catherine Tsai和冯立强可以在疫苗开发方面有进一步的接触与合作。MD ABDUL MAZID向Daniel Conole表达使用其药物筛选系统进行合作研发的意向。李尹雄就相关科研问题向Peter Mace、Bo Liu和Emma Scotter提问。同时Daniel Conole对巫林平和张骁的研究方向表现出浓厚兴趣。
During the roundtable discussion, 10 researchers from New Zealand and 6 from China each gave a thematic presentation, covering topics such as infectious disease control, vaccine development, metabolic diseases and phenotypic regulation, precise diagnosis and treatment of tumors, neurodegenerative diseases, drug development technologies, and reproductive development. They all expressed their willingness to collaborate in these research areas. After the roundtable discussion, both sides engaged in enthusiastic discussions. Dean Sun Fei suggested that Catherine Tsai and Feng Liqiang could further engage in cooperation in vaccine development. MD Abdul Mazid expressed his intention to collaborate and develop research using Daniel Conole's drug screening system. Li Yinxiong asked Peter Mace, Bo Liu, and Emma Scotter questions about related research issues. At the same time, Daniel Conole showed a strong interest in Wu Linping and Zhang Xiao's research directions.
后期组队合作计划讨论
Discussion on Later Team Collaboration Plans
孙飞总结后期的合作方向主要是围绕以下四个方向：
Dean Sun Fei summarized that the main directions for later collaboration would focus on the following four areas:
谱系设施：作为核心平台，支持跨学科研究；
Lineage Facilities: As a core platform, supporting interdisciplinary research;
药物研发：疫苗开发、探索新技术保护与专利申请；
Drug Development: Vaccine development, exploring new technologies for protection and patent applications;
大动物模型：推动异种移植及其他领域的应用；
Large Animal Models: Promoting xenotransplantation and other applications;
免疫治疗：开发新型免疫疗法mRNA治疗。
Immunotherapy: Developing novel immunotherapies, such as mRNA treatments.
此外，孙飞就更有效地交流，建立高效的沟通机制提出了四点建议：
In addition, Sun Fei proposed four suggestions for more effective communication and establishing an efficient communication mechanism:
建立电子邮件群，便于交流想法或提出其他请求；
Set up an email group to facilitate the exchange of ideas or other requests;
使用微信手机聊天工具，由Peter Lai组建一个微信群，加快中新双方人员互动速度；
Use WeChat for mobile messaging, with Peter Lai forming a WeChat group to speed up interactions between Chinese and New Zealand personnel;
保持定期举办季度线上研讨会，分享最新研究成果；
Regularly hold quarterly online seminars to share the latest research findings
建设专门的中新联合实体实验室，提供实验与办公空间，欢迎新方研究人员来华开展研究。
Establish a dedicated Sino-New Zealand joint entity laboratory to provide experimental and office space, welcoming New Zealand researchers to conduct research in China.
闭幕总结
Closing Summary
新方代表Emily Parker再次感谢中方的热情接待，并呼吁双方继续推进合作，寻找新的连接方式。
Emily Parker, a representative from New Zealand, thanked the Chinese side for their warm hospitality and called for both sides to continue advancing their cooperation and finding new ways to connect.
蔡陈崚（广州健康院副院长）在2025中国—新西兰生物医药双边研讨会闭幕致辞中提到：GIBH以充足经费与尖端设备为基石，正加速落成可容纳20,000笼SPF小鼠的智能化实验动物平台，并同步建设兼具实验、办公区域的中新联合实验室（预计2025年投入使用）。面向未来，我们将深度融合临床、人工智能与细胞谱系图谱，打造个性化、高效的治疗创新平台；通过空间组学、CRISPR等关键技术联合研讨会，以及季度线上研讨、年度面对面会议、皇后镇研究周等常态化交流活动，持续激发跨国协作活力；积极争取MBIE与CAS资金支持。同时，诚邀新西兰科学家来华开展短期访问与推进研究生联合培养计划，培养具有全球视野的新一代科学家。并建设在线数据共享平台，打破地域壁垒，构建长期可持续的科研生态。
Cai Chenling, deputy director of the Guangzhou Institute of Biomedicine and Health (GIBH), mentioned in his closing remarks at the 2025 China-New Zealand Biomedical Bilateral Symposium: GIBH, with ample funding and advanced equipment, is accelerating the construction of an intelligent experimental animal platform that can accommodate 20,000 SPF mice cages, while simultaneously building a Sino-New Zealand joint laboratory with both experimental and office areas (expected to be operational in 2025). Looking to the future, we will deeply integrate clinical, artificial intelligence, and cell lineage mapping to create a personalized and efficient platform for innovative treatments; through joint symposiums on spatial genomics, CRISPR, and other key technologies, as well as regular online seminars, annual face-to-face meetings, and Queenstown Research Week, we will continuously stimulate the vitality of international collaboration; we will actively seek funding support from MBIE and CAS. At the same time, we sincerely invite New Zealand scientists to conduct short-term visits in China and advance the joint training program for graduate students, nurturing the next generation of scientists with a global perspective. We will also build an online data sharing platform to break down geographical barriers and construct a long-term sustainable research ecosystem.